Development of T-cell engagers selective for cells co-expressing two antigens

T cell-engaging bispecific antibodies (TCEs) are clinically effective treatments for hematological cancers. While the utility of TCEs in solid malignancies is being explored, toxicities arising from antigen expression on normal tissues have slowed or halted several clinical trials. Here, we describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Dicara, Danielle M., Bhakta, Sunil, Go, Mary Ann, Ziai, James, Firestein, Ron, Forrest, Bill, Gu, Chen, Leong, Steven R., Lee, Genee, Yu, Shang-Fan, Polson, Andrew G., Agard, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553182/
https://www.ncbi.nlm.nih.gov/pubmed/36206404
http://dx.doi.org/10.1080/19420862.2022.2115213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553182/
https://www.ncbi.nlm.nih.gov/pubmed/36206404
http://dx.doi.org/10.1080/19420862.2022.2115213

Ejemplares similares